Eligi
Med
Base de datos
Seguridad
Sobre EligiMed
Contacto
Contáctenos
Ensayos Clínicos | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment With RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)
INTERVENTIONAL
Inicio: 1 de nov de 2015
ID: NCT02586155
Completado
Fase 3
ClinicalTrials.gov
A Double-blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer
INTERVENTIONAL
Inicio: 1 de nov de 1998
ID: NCT00241449
Completado
Fase 3
ClinicalTrials.gov
A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
INTERVENTIONAL
Inicio: 12 de nov de 2015
ID: NCT02597933
Completado
ClinicalTrials.gov
Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation
OBSERVATIONAL
Inicio: 20 de ago de 2014
ID: NCT02141438
Completado
Fase 4
ClinicalTrials.gov
SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects With Asthma
INTERVENTIONAL
Inicio: 18 de nov de 2011
ID: NCT01475721
Completado
Fase 2
ClinicalTrials.gov
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
INTERVENTIONAL
Inicio: 1 de oct de 2010
ID: NCT01197794
Completado
Fase 3
ClinicalTrials.gov
A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).
INTERVENTIONAL
Inicio: 1 de dic de 2009
ID: NCT01000727
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
INTERVENTIONAL
Inicio: 19 de oct de 2021
ID: NCT04963270
Completado
Fase 3
ClinicalTrials.gov
BAX 326 (Recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B - A Continuation Study
INTERVENTIONAL
Inicio: 12 de abr de 2011
ID: NCT01286779
Completado
Fase 2
ClinicalTrials.gov
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults With Moderate to Severe Uncontrolled Asthma
INTERVENTIONAL
Inicio: 27 de ene de 2022
ID: NCT05251259
Terminado
Fase 2
ClinicalTrials.gov
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
INTERVENTIONAL
Inicio: 1 de feb de 2011
ID: NCT01489046
Completado
Fase 4
ClinicalTrials.gov
A 26 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group, Treat-to-target Once Daily Treatment Trial With Insulin Detemir Versus Insulin Glargine, Both in Combination With Metformin in Subjects With Type 2 Diabetes
INTERVENTIONAL
Inicio: 1 de may de 2009
ID: NCT00909480
Completado
Fase 2
ClinicalTrials.gov
A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib
INTERVENTIONAL
Inicio: 20 de mar de 2009
ID: NCT00777036
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Glyburide Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone
INTERVENTIONAL
Inicio: 1 de jul de 2003
ID: NCT00162175
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
INTERVENTIONAL
Inicio: 30 de oct de 2019
ID: NCT04133909
Completado
Fase 3
ClinicalTrials.gov
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE-AHF]
INTERVENTIONAL
Inicio: 1 de jul de 2012
ID: NCT01661634
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist.
INTERVENTIONAL
Inicio: 13 de jun de 2014
ID: NCT02161757
Completado
ClinicalTrials.gov
Effectiveness of a High-risk Diabetic Patients Program
INTERVENTIONAL
Inicio: 1 de mar de 2010
ID: NCT01051245
Completado
Fase 3
ClinicalTrials.gov
MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC
INTERVENTIONAL
Inicio: 9 de jul de 2019
ID: NCT03905330
Completado
Fase 4
ClinicalTrials.gov
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
INTERVENTIONAL
Inicio: 17 de mar de 2016
ID: NCT02654145
Anterior
1
...
407
408
409
...
434
Siguiente
Filtros